Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J
PharmaVoice
Pharmaceutical Manufacturing
Washington, District of Columbia 11,834 followers
Covering everything from Molecule to Market
About us
PharmaVoice is for life-sciences executives and other healthcare-service related professionals. The primary audience is made up of executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors. Additionally, PharmaVoice.com has readers from around the world. Subscribe to the daily newsletter at https://dive.pub/3ruPmUL
- Website
-
http://www.pharmavoice.com
External link for PharmaVoice
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Washington, District of Columbia
- Type
- Privately Held
- Specialties
- pharmaceutical, biotechnology, medical devices, life sciences, advertising, marketing, publishing, digital media, editorial, content generation, digital marketing, and marketing strategy
Locations
-
Primary
1100 15th St NW
4th Floor - (Suite 178)
Washington, District of Columbia 20005, US
Employees at PharmaVoice
Updates
-
Results from Vaxcyte’s clinical #pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster #Prevnar. https://lnkd.in/gP-QJtT6
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
pharmavoice.com
-
As the FDA considers eliminating advisory committee votes from the drug approval process, adcomm members vie to have their voices heard. #drugdevelopment #pharma 3D Communications, LLC https://lnkd.in/gaC3MsTq
FDA adcomm reform talks heat up
pharmavoice.com
-
A slew of breakthrough #gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns. Here’s a look at the sales performance for some of the most innovative and expensive therapies approved in recent years. Orchard Therapeutics - U.S. #Lenmeldy Vertex Pharmaceuticals CRISPR Therapeutics #Casgevy CSL Behring B.V. #Hemgenix BioMarin Pharmaceutical Inc. #Roctavian Sarepta Therapeutics #Elevidys https://lnkd.in/e377rc-Y
Is anyone taking the world’s priciest drugs?
pharmavoice.com
-
PharmaVoice reposted this
Thanks for the write up PharmaVoice and Michael Gibney - Their Alzheimer’s treatment worked — but shares fell anyway - #AlzheimersDisease #clinicaltrials https://lnkd.in/e7mGvrhV
Their Alzheimer’s treatment worked — but shares fell anyway
pharmavoice.com
-
By rejecting the Lykos Therapeutics' MDMA therapy earlier this month, the FDA signaled to the #psychedelic drug sector that the road to approval isn’t clear cut. “The FDA’s decision has put the sector on notice that [the agency] will not accept any short cuts,” says Doug Drysdale, CEO of Cybin Inc https://lnkd.in/gSq36A4K
After an FDA rejection, here’s what’s next in the psychedelics pipeline
pharmavoice.com
-
Dr. Phuong Khanh (PK) Morrow took over Takeda’s oncology therapeutic area unit earlier this year and has spent the past several months honing and evolving its strategy. Morrow is drawing from not only her history-making experience at CRISPR Therapeutics, but also as a physician at MD Anderson Cancer Center and later, her years at Amgen. “Cancer is so aggressive that we cannot let a day go by without advancing these programs," she said. We spoke to Morrow about her focus at Takeda and the company’s revamped #oncology strategy. https://lnkd.in/g2xNkiey
With a new oncology R&D head, Takeda revamps its strategy
pharmavoice.com
-
“Hallucinations” represent one of the challenges to widespread use of AI and machine learning. In a healthcare setting, the introduction of false information into the algorithms can be especially harmful, says Wael Salloum, Ph.D., co-founder and chief science officer at natural language processing company Mendel.ai https://lnkd.in/gaBxSuMq
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
pharmavoice.com
-
SIGA Technologies recently reported that its antiviral #Tpoxx didn’t clear the mpox's hallmark blistering rash faster than placebo in a government-sponsored trial. But if you ask Dr. Jay K. Varma, Siga’s chief medical officer, the discouraging data doesn’t point to a drug that doesn’t work — it revealed a flawed endpoint selection. #mpox https://lnkd.in/eRsTV2UE
As a new mpox strain gains ground, a key drug stumbles in the clinic
pharmavoice.com
-
Before the #IRA established price negotiations on behalf of #Medicare, industry insiders were concerned the cost cuts would bring about an exodus in #pharma investment. But according to a new analysis from Center for Integration of Science and Industry at Bentley University, those estimates were likely exaggerated. https://lnkd.in/eB47Wk4E
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
pharmavoice.com